Business
Trump TikTok
President Trump hopes he can save TikTok (Jaap Arriens/Getty Images)
TikTok shop

TikTok US is worth only $14 billion, according to the Trump-backed deal

Charting how that stacks up against the rest of the social media landscape suggests Oracle, Silver Lake, and MGX got a pretty sweet deal.

Hyunsoo Rim

So, we finally have a TikTok US deal, as President Trump signed an executive order to push forward an agreement requiring ByteDance to divest TikTok’s US operations.

But rather than settling every question, the price tag is raising more of them, with some analysts calling it “the most undervalued tech acquisition of the decade” or a “daylight robbery.”

The deal would create a new US-based joint venture, majority-owned by American investors. Oracle, Silver Lake, and the Abu Dhabi-based investment firm MGX are slated to hold 45% of the company — split roughly 15% each — according to CNBC. Meanwhile, ByteDance’s stake will be capped at 19.9% to comply with national security rules, with the remaining 35% in the hands of new investors and existing ByteDance backers, including General Atlantic, Susquehanna, and Sequoia.

So, what is the world’s most addictive app, which counts more than 180 million active users in the US, worth? Some $14 billion, per Vice President JD Vance — far below earlier projections of $40 billion to $50 billion.

Though not an apples-to-apples comparison — as these other sites have global user bases — TikTok US would be by far the cheapest among its peers, whose latest valuations all easily top $14 billion.

TikTok
Sherwood News

The discount stands out even more when measured against sales: Snap trades at 2.5x, Pinterest at 5.9x, and Reddit at 25.3x their trailing 12-month revenues, while TikTok US is priced at roughly 1x its estimated annual US revenues of $10 billion to $20 billion.

Thursday’s order gives 120 days to close — the fifth deadline extension since the divest-or-ban law took effect — now putting it at January 2026. Trump said he had received Chinese President Xi Jinping’s personal approval, though Beijing has yet to publicly confirm.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.